Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FBXW7 inact mut |
| Therapy | RP-3500 + RP-6306 |
| Indication/Tumor Type | endometrial cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FBXW7 inact mut | endometrial cancer | predicted - sensitive | RP-3500 + RP-6306 | Phase I | Actionable | In a Phase I trial (MYTHIC), treatment with the combination of RP-6306 and RP-3500 in ovarian or endometrial cancer patients harboring CCNE1 amplification, FBXW7 mutations, and/or PPP2R1A mutations resulted in a clinical benefit rate (CBR) of 79%, a median progression-free survival (mPFS) of 21 weeks, and a response rate of 38% in ovarian cancer (n=24), and a CBR of 48%, mPFS of 17 weeks, and a response rate of 26% in endometrial cancer (n=27) (Cancer Res (2025) 85 (8_Supplement_2): CT262; NCT04855656). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) | Full reference... |